Electrical Geodesics, Inc. (EGI) Licenses Key Technology for EEG/fMRI Recording from UCLA
|
 |
Wednesday, 26 November 08 - 01:22 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
Eugene, Oregon - November 18, 2008 - New techniques for imaging the functional activity of the human brain by simultaneously recording changes in its electrical activity (EEG) and blood flow (fMRI) are contributing important insights into normal and pathological brain functioning. However, the EEG signal recorded with existing EEG/fMRI technologies is often of disappointing quality.
Today, EGI announced that it had licensed a key patent from The Regents of the University of California covering methods for improving the signal quality of the EEG when it is recorded during an MRI exam (U.S. Patent No. 7,286,871, “Method and apparatus for reducing contamination of an electrical signal”). The licensed techniques, developed by Dr. Mark Cohen of UCLA’s David Geffen School of Medicine, allow the artifact introduced into the recorded EEG signal by the large gradient pulses emitted by the MRI during its normal operation to be effectively removed from the data using timing pulses generated by the MRI. Additional claims in the patent protect the use of “twisted” pairs electrodes to help improve the signal-to-noise ratio, which also results in cleaner EEG recordings. [company pr] MORE
NanoPacific Announces Two New Exclusive Licensed Technologies Invented at UCLA -- Nanoemulsions and Polypeptides
|
|
|
Sunday, 16 November 08 - 12:19 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
UCSD Technology Licensed by Urigen Pharmaceuticals
|
|
|
Saturday, 13 September 08 - 06:13 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
"For the millions of sufferers of a bladder condition called painful bladder syndrome/interstitial cystitis, hope is on the way, developed by urologic surgeon and researcher Lowell Parsons, M.D. of the University of California, San Diego Medical Center.
"What our team has identified is an experimental drug therapy that can provide pain relief to patients within 20 minutes," said Parsons, professor of surgery at UC San Diego School of Medicine. "Depending on the individual, in my experience, one dose can last from 6 to 40 hours. The ability of the therapy to provide immediate relief is something entirely new for sufferers of interstitial cystitis."
"The new drug therapy combination has been licensed by UC San Diego Technology Transfer & Intellectual Property Services to Urigen Pharmaceuticals, Inc. for further clinical development and commercialization. [MedicalNewsToday] MORE
Raptor Pharmaceutical Inc. Enters Collaboration Agreement with University of California, San Diego (UCSD) in Liver Disease
|
|
|
Thursday, 24 July 08 - 09:31 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
Under the terms of the Agreement, clinical researchers from UCSD will perform the Phase 2a study at the University's General Clinical Research Center, and Raptor will provide funding and clinical supply of Cysteamine. In March 2008, Raptor acquired an exclusive, worldwide license to certain intellectual property and development rights from UCSD surrounding the use of Cysteamine as a potential treatment for NASH. [biospace] MORE
Neoprobe Expands Access to UCSD Developed Technology
|
|
|
Monday, 12 May 08 - 03:08 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
"DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that Neoprobe and the University of California, San Diego (UCSD) have executed a definitive license agreement involving development rights to a molecular compound developed by researchers at UCSD. The new agreement accords Neoprobe the right to develop products using the compound for human medical applications incorporating optical or ultrasound technology. In addition, the development rights to the compound have been expanded to include veterinary applications. The compound is covered by U.S. patent 6,409,990 and corresponding issued patents in the European Union and Japan.
"William Decker, Assistant Director of the Office of Technology Transfer and Intellectual Property Services of UCSD, said, "We're pleased that our office could assist in working with Neoprobe to bring an additional use of this technology to the public at-large." [BusinessWire] MORE
UCSD Technology Licensed by Memgen, Inc. in Clinical Trials for Chronic Lymphocytic Leukemia
|
|
|
Wednesday, 05 December 07 - 06:06 AM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
Patients with chronic lymphocytic leukemia (CLL) who have failed chemotherapy or have chosen to forego chemotherapy have an opportunity to participate in a new clinical trial for a CLL vaccine being conducted at the Moores Cancer Center at the University of California, San Diego (UCSD).
Study participants will receive Memgen’s ISF35, an immune therapy product, or vaccine. Based on the results of previous studies, ISF35 has the potential to stimulate the immune system to act against CLL cells and fight them naturally. Memgen, a biomedical company headquartered in Dallas, Texas, licensed the technology for the ISF35 molecule from UCSD and continues clinical development of the molecule.
ISF35 is an abbreviation for Immune Stimulatory Factor 35, which is an offspring of technology discovered by Thomas J. Kipps, M.D., Ph.D., professor in the UCSD Department of Medicine and deputy director for research at the Moores Cancer Center.
“ISF35 gene therapy represents the next generation of leukemia-targeting vaccine strategies for patients with CLL,” said Kipps. “It is designed to activate dormant leukemia B-cells and rally T-cells to selectively attack blood- and tissue-based leukemia cells.” [ucsd press release]MORE
Neuralstem Obtains UCSD Stem Cell Delivery System for Use in Spinal Cord Trials
|
|
|
Wednesday, 05 December 07 - 05:45 AM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
" ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCall/ -- Stem cell company, Neuralstem, Inc. , today announced that it has exclusively licensed the "Spinal Multisegmental Cell and Drug Delivery System," invented by Dr. Martin Marsala at the University of California, San Diego (UCSD). The exclusive, worldwide license to Neuralstem covers all fields of use and includes the right to grant sublicenses. Under the terms of the agreement, UCSD will be eligible for milestone payments and royalties and Neuralstem will assume the cost of development, manufacture and approval of the product.
"The device provides a unique method for delivering cells horizontally along the length of the spinal cord," said Dr. Marsala, "which will reduce the number of entry sites needed for therapeutic intervention. We believe that this will greatly enhance the likelihood of success for treating many indications." Dr. Marsala went on to say, "Neuralstem has not only shown a strong commitment to moving their spinal cord stem cells into the clinic, but to creating a therapy that can be broadly and safely delivered. We are excited to have them as our exclusive licensee for this important technology." [press release]MORE
UC Riverside Research Leads to Self-Improving Chips with Speed ‘Warping’
|
|
|
Thursday, 18 October 07 - 07:28 AM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
A new, patent-pending technology developed over the last five years by UCR’s Frank Vahid, Professor of Computer Science and Engineering, called "Warp processing" gives a computer chip the ability to improve its performance over time. The benefits of Warp processing are just being discovered by the computing industry. A range of companies including IBM, Intel and Motorola’s Freescale have already pursued licenses for the technology through UCR’s funding source, the Semiconductor Research Corporation.
“Thread Warping: A Framework for Dynamic Synthesis of Thread Accelerators” was named one of the top five papers at the 2007 International Conference on Hardware/Software Codesign and System Synthesis (CODES/ISSS) conference in Austria, and was published among the conference proceedings. “Warp Processing and Just-in-Time FPGA Compilation,” the Ph.D. dissertation of Vahid’s student Roman Lysecky, was named “Dissertation of the Year” by the European Design and Automation Association in 2006. [UCR press release] MORE
AmberWave Systems and UCSB Partner to Develop Pioneering Technologies with Mesoporous Materials
|
|
|
Tuesday, 09 October 07 - 04:42 AM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
Materials Science in-Licensing Agreement to have Broad, Commercial Market Applications
Salem, N.H. – October 4, 2007 – AmberWave Systems, a leader in the research, development and licensing of advanced technologies for semiconductor manufacturing, announces an in-licensing agreement with the University of California, Santa Barbara (UCSB) to collaborate on, and fund, materials science research within the field of mesoporous materials.
UCSB is among the leading academic institutions pursuing work in the field of mesoporous and mesostructured materials, which encompasses electrical generation and storage in the form of fuel cells, high-performance batteries and ultracapacitors. The acquisition of this technology will expand AmberWave’s holdings of materials science within its portfolio of already existing silicon germanium and aspect ratio trapping (ART) platform technologies. Mesoporous materials will also broaden the scope of AmberWave applications beyond semiconductors.
“AmberWave’s vision of commercialization of materials science technologies was a primary motivation for us to seek a partnership with them,” said Professor Brad Chmelka of the Department of Chemical Engineering at UCSB and one of the co-inventors of the technology. “Furthermore, AmberWave’s commitment to continued development of the technology makes them an ideal candidate to move these ideas from the university laboratory to the marketplace.” [company press release] MORE
Cortex and the University of California, Irvine Extend Exclusive Licensing Agreement
|
|
|
Thursday, 14 June 07 - 03:39 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
" 'Cortex and UCI have enjoyed an excellent working relationship with Professors Gary Lynch, Ph.D., the distinguished UCI neuroscience professor and inventor of the AMPAKINE(R) technology, and David Schetter, the Assistant Vice Chancellor of the Office of Technology Alliances at the University," said Roger G. Stoll, Ph.D., Cortex's Chairman, President and Chief Executive Officer. "We are grateful for their support and Cortex is fully committed to diligently move the AMPAKINE technology to commercialization." [PharmaLive] MORE
Television Just Got Brighter: UCLA Engineers Are Obsessed With Next Generation Of LEDs
|
|
|
Thursday, 17 May 07 - 03:44 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
" Two researchers at the UCLA Henry Samueli School of Engineering and Applied Science want to make sure future generations of plasma TV watchers will see games like the upcoming NBA Finals in the brightest, most beautiful color possible -- for a lot less money.
" 'The current results represent our ongoing quest to create better, slimmer, less expensive high-performance PLEDs," Yang said. "Using our simple solution method, we already have successfully achieved several world records in device efficiency, including 20 lumens/watt white emission fluorescent PLEDs, 30 lumens/watt green emission fluorescent PLEDs and 18 lumens/watt red emission phosphorescent PLEDs. So our latest red emission PLED is just one of our multiple records. It's a very exciting development.'
" The new technology, which already has been licensed by Canon, should be available to consumers in about three years. [ScienceDaily] MORE
Cyberlux claims hybrid organic/inorganic lighting better than LEDs
|
|
|
Wednesday, 31 January 07 - 05:24 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
" Cyberlux Corp of Research Triangle Park, Durham, NC, USA intends to introduce lighting products created through the combination of the hybrid organic/inorganic white and multi-color lighting technology acquired from the University of California-Santa Barbara (UCSB) with the Scattered Photon Extraction (SPE) technology acquired from Rensselaer Polytechnic Institute. [semiconductorToday] MORE
Diamyd On Target for Phase III Studies
|
|
|
Wednesday, 31 January 07 - 05:15 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
" Diamyd Medical announces today that the Company has had a Type B, End of Phase II meeting, with the United States Food and Drug Administration, FDA, on the 29th of January, 2007 in Washington DC. The meeting related to the Phase III clinical program with Diamyd® in type 1 diabetes and was held with a Diamyd team of about 15 people and about an equal number of people from the FDA.
Diamyd Medical has an exclusive world-wide license from UCLA in Los Angeles regarding the therapeutic use of the GAD65 gene. [PRNewswire] MORE
Blaze DFM Opens San Diego Development and Support Center
|
|
|
Tuesday, 30 January 07 - 08:19 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
" SUNNYVALE, Calif.--(BUSINESS WIRE)--Blaze DFM, Inc., the electrical DFM company, today announced the opening of a development and support center in San Diego, California. The facility will be managed by Dr. Cho Moon. Over the past two years, Dr. Moon has led research and development for timing analysis and infrastructure as well as multiple customer product tapeout engagements.
“With the successful launch of the company and shipment of our first products behind us, the time is right to open a facility in San Diego,” remarked Jacob Jacobsson, president and CEO at Blaze. “Much of our initial intellectual property was developed at, and licensed from, the University of California at San Diego (UCSD), and we want to continue to tap into the DFM talent pool there. Also, one of our largest customers, Qualcomm, is located in San Diego and as they proliferate the use of Blaze products, the support requirements justify having a local office. The semiconductor and EDA industries have acknowledged the importance of electrical DFM, a concept pioneered by Blaze, in addressing the ever-growing interdependencies between design and manufacturing. [BusinessWire] MORE
Technology Patent & Licensing News
|
|
|
Monday, 15 January 07 - 04:37 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
Prometheus Exclusive Licensee of Recently-Issued Patent - OmpC Antigen Included in Diagnostic Test for Crohn's Disease
" SAN DIEGO, Jan. 4 /PRNewswire/ -- Prometheus Laboratories Inc. announced the issuance of U.S. Patent #7,138,237 for the diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen. This proprietary technology is used in the new Prometheus(R) IBD Serology 7 diagnostic test, the Company's recently launched and most advanced test for inflammatory bowel disease (IBD). Prometheus had previously licensed exclusive rights to the technology under an agreement with Cedars-Sinai Medical Center and the Regents of the University of California (UCLA). [PRNewswire] MORE
Imaging Method Detects Alzheimer's Risk
Photonics.com, MA -
" ... trial using the new molecular marker to obtain Food and Drug Administration approval. UCLA owns a patent on the approach and has licensed it to Siemens. MORE
Cheaper LEDs from Breakthrough in Nanowire Research
" SAN DIEGO, Jan. 9, 2007 - Engineers at UC San Diego have synthesized a long-sought semiconducting material that may pave the way for an inexpensive new kind of light emitting diode that could compete with today's widely used gallium nitride LEDs, according to a new paper in the journal Nano Letters [greenbiz] MORE
... More items are available in my News Archive
